LifeStance Health Q4 revenue beats on higher visit volumes

LifeStance Health

25/02/2026 11:14

Overview

Mental healthcare provider's Q4 revenue rose 17%, beating analyst expectations

Adjusted EBITDA for Q4 beat analyst expectations

Company announced $100 mln share repurchase program

Outlook

LifeStance expects 2026 revenue of $1.615 bln to $1.655 bln

Company anticipates 2026 Center Margin of $526 mln to $550 mln

LifeStance projects 2026 Adjusted EBITDA of $185 mln to $205 mln

Result Drivers

VISIT VOLUMES - Revenue growth driven by higher visit volumes from clinician growth and improved productivity

OPERATING LEVERAGE - Adjusted EBITDA increased due to revenue growing faster than general and administrative expenses

CLINICIAN EXPANSION - Clinician base increased 9% to 8,040, supporting higher visit volumes

Company press release: ID:nGNX3279mj

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$382.20 mln
$376.31 mln (9 Analysts)
Q4 EPS
$0.02
Q4 Net Income
$11.70 mln
Q4 Adjusted EBITDA
Beat
$48.80 mln
$40.30 mln (8 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for LifeStance Health Group Inc is $8.50, about 19% above its February 24 closing price of $7.14

The stock recently traded at 165 times the next 12-month earnings vs. a P/E of 173 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)